Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma

Our plain-English summary of Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma, by Y.R. Li, Y. Zhu, Z. Li, et al (Research, 2026).

The study

• Authors: Y.R. Li, Y. Zhu, Z. Li, X. Shen, S. Li, Y. Chen, Z. Lyu, J. Huang, N.Y. Ma, C. Zhang, A.S. Zhao, Y. Tian, X.J. Zhou, L. Yang
• Journal: Research
• Published: 2026;9:1310
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy arising from the pleural lining, characterized by a dismal prognosis and limited therapeutic options. Mesothelin (MSLN)-directed chimeric antigen receptor (CAR)-armored T (CAR-T) cell therapies have shown encouraging preliminary outcomes; however, autologous manufacturing approaches remain constrained by logistical complexity and prolonged production timelines, which are suboptimal for patients with rapidly advancing disease. Here, we describe the development of human allogeneic interleukin-15-augmented, MSLN-specific, CAR-armored invariant natural killer T (Allo15MCAR-NKT) cells. These cells are generated through genetic modification of hematopoietic stem and progenitor cells, followed by a clinically guided CAR-NKT cell differentiation, maturation, and expansion process. This approach supports scalable production with high cellular yield, purity, and translational feasibility. Functionally, Allo15MCAR-NKT cells exhibit robust antitumor efficacy in vitro and demonstrate robust therapeutic activity across multiple in vivo MPM xenograft models, including subcutaneous and lung metastasis models. In addition, they actively modulate the tumor microenvironment by targeting CD1d+ tumor-associated macrophages. Phenotypic analysis reveals a rejuvenated cellular profile, marked by low expression of exhaustion-associated and inhibitory receptors, including PD-1, TIM-3, LAG-3, CTLA-4, and TIGIT, consistent with sustained functional capacity. Importantly, these cells display a favorable safety profile, with minimal evidence of graft-versus-host disease, cytokine release syndrome, brain infiltration or neurotoxicity, and no detectable off-tumor effects. Collectively, these findings support the development of a clinically translatable, off-the-shelf CAR-NKT cell therapy for the treatment of MPM.

Copyright © 2026 Yan-Ruide Li et al.

In plain English

This was a laboratory and animal (preclinical) study describing the manufacture and testing of allogeneic, interleukin-15-augmented, mesothelin (MSLN)-directed CAR-armored invariant natural killer T cells (Allo15MCAR-NKT), made by lentiviral engineering of cord blood CD34+ hematopoietic stem and progenitor cells followed by a six-week feeder-free differentiation culture. The authors first re-analysed published single-cell RNA sequencing data from 13 treatment-naive malignant pleural mesothelioma (MPM) patients and reported MSLN as the most favourable of five candidate CAR targets. The manufactured cells reached greater than 97% purity, and the authors reported expansion sufficient for an estimated 1,000 to 10,000 clinical doses from one cord blood unit. Against mesothelioma cell lines and in subcutaneous and lung-metastatic MPM xenograft mouse models, Allo15MCAR-NKT cells showed greater tumour control than PBMC-derived CAR-NKT or conventional CAR-T cells, killed CD1d+ M2 macrophages, and carried low levels of PD-1, TIM-3, LAG-3, CTLA-4 and TIGIT. In the safety experiments, mice given these cells showed no clinical signs of graft-versus-host disease, no weight loss or rise in the measured CRS biomarkers (which the authors described as suggesting reduced CRS potential), and no detectable brain accumulation at day 30, whereas conventional CAR-T cells did. Anti-TIM-3 antibody added further benefit. Apart from the re-analysis of patient tumour sequencing data, efficacy and safety were tested only in cell cultures and mice and have not been established in patients.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Preclinical laboratory and animal study (cell manufacturing, in vitro assays, mouse xenograft experiments), with re-analysis of published patient single-cell RNA sequencing data
• Who was studied: Published single-cell RNA sequencing data from 13 treatment-naive MPM patients covering epithelioid, sarcomatoid and biphasic subtypes; commercially sourced cord blood CD34+ HSPCs and healthy-donor PBMCs; human tumour cell lines (H226, MSTO, MM.1S, A375, K562, OVCAR8); NSG, NSG-SGM3 and NSG-MHC I/II DKO mice, 6 to 10 weeks old, at UCLA
• Exposure: Allogeneic HSPC-derived CAR-NKT cells carrying one lentivector encoding the invariant NKT TCR, a third-generation MSLN-directed CAR (SS1 scFv with CD28 and 4-1BB) and soluble IL-15; compared with PBMC-derived IL-15-augmented CAR-NKT cells, conventional MSLN CAR-T cells, PBMC NK and CAR-NK cells; mouse doses of 1 x 10^6, 3 x 10^6 and 1 x 10^7 cells
• Main results:
  • In the re-analysis of the 13 patient samples, MSLN showed the highest and most consistent expression of the five CAR targets examined (MSLN, EGFR, HER2, FAP, MET)
  • Manufactured Allo15MCAR-NKT cells reached more than 97% purity (10 cord blood donors), with over 50% of CD34+ HSPCs transduced
  • From one cord blood unit of about 5 million CD34+ HSPCs, the process yielded more than 10 to the 12th cells, which the authors estimated as 1,000 to 10,000 clinical doses
  • In 24-hour killing assays the Allo15MCAR-NKT cells killed both MSLN-positive and MSLN-negative tumour cells, more strongly than the comparator cell products; blocking NKG2D and DNAM-1 reduced killing
  • In the H226-FG subcutaneous MPM xenograft NSG mouse model, Allo15MCAR-NKT cells suppressed tumour more than PBMC-derived CAR-NKT or conventional CAR-T cells, while CAR-T cells killed mice through graft-versus-host disease
  • In the H226-FG metastatic (intravenous) xenograft model, Allo15MCAR-NKT cells gave the greatest tumour reduction and longest mouse survival of the three cell products, though some mice relapsed and died
  • Adding an anti-TIM-3 antibody (sabatolimab biosimilar, 10 mg/kg weekly) to Allo15MCAR-NKT cells in the metastatic model improved tumour control and survival further
  • Tumour-infiltrating Allo15MCAR-NKT cells carried lower inhibitory receptor levels than the comparator products
  • Allo15MCAR-NKT and PBMC-derived CAR-NKT cells killed CD1d+ M2-polarised macrophages in an alpha-GC and CD1d-dependent way, whereas conventional CAR-T cells did not kill them
  • In the CRS experiment, mice given Allo15MCAR-NKT or PBMC-derived CAR-NKT cells showed no body weight loss and no rise in the measured CRS biomarkers, which the authors said suggested reduced CRS potential
  • In the brain infiltration experiment, brain tissue bioluminescence at day 30 detected only conventional CAR-T cells, not the two CAR-NKT products
  • In both NSG and NSG-MHC I/II DKO mice, neither CAR-NKT product produced detectable clinical signs of graft-versus-host disease
• The authors' conclusion: The authors concluded that the HSPC-engineered, IL-15-augmented MSLN CAR-NKT cell product combines scalable off-the-shelf manufacturing, multimodal tumour targeting, low exhaustion and a favourable safety profile in preclinical models, providing a basis for clinical translation in MPM
• Limitations the authors state:
  • The in vivo experiments used high cell doses, which may have accelerated xenogeneic graft-versus-host disease in the CAR-T group and complicated comparisons
  • Xenogeneic graft-versus-host disease seen in mice may not be relevant to clinical autologous CAR-T therapy
  • No direct comparison was made with current standard-of-care MPM treatment, and immunodeficient xenograft models cannot fully model such therapies
  • Low checkpoint expression alone is not enough to define a low-exhaustion phenotype; functional and transcriptional exhaustion programs were not fully assessed
  • The relevance of the TIM-3/galectin-9 pathway in tumours with low or absent galectin-9 remains undefined
  • The three-dimensional cultures were spheroid-like aggregates of cell lines, not classical patient-derived organoids
  • Patient-derived xenograft and nonhuman primate studies were not done and are needed for translation
  • Residual HLA expression left some measurable alloreactivity against the product

Topics

Medical terms in this study, explained in our Lexicon: STEM, Pleural Mesothelioma, Prognosis, Mesothelin, Metastasis, Tumor Microenvironment, Macrophage, CTLA-4.

Related studies

• Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2 — B.W. Robinson (1989)
• Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients — Y. Nishimura, N. Kumagai-Takei, et al. (2015)
• Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy — H. Wu, Y. Wang, et al. (2024)
• Lymphocyte subsets in subjects exposed to asbestos: changes in circulating natural killer cells — N. al Jarad, M. Macey, et al. (1992)
• Natural killer cell activity in asbestos workers. Interactive effects of smoking and asbestos exposure — R.D. deShazo, J. Morgan, et al. (1988)
• Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients — E. Altomare, S. Fallarini, et al. (2012)

Browse return to medical research.